Summary: An unknown guanidino-positive compound peak has been identified in urines of three sisters affected with hyperargininaemia. Identification was made on the basis of its similarity with the liquid and thin-layer Chromatographie characteristics of enzymatically synthesized 2-oxo-5-guanidinovaleric acid. Identification was also made by combined gas chromatography -mass Spectrometry of the unknown compound peak. The synthesis of enzymatically formed 2-oxo-5-guanidinovaleric acid was controlled by nuclear magnetic resonance and combined gas chromatography -mass Spectrometry.
Introduction
Figure l gives the different monosubstituted guanidino An unknown guanidino-positive compound peak was compounds in parallel with the amino acids, in urine of previously shown by liquid chromatography in the urine the patients. The concentrations of the guanidino comof three sisters affected with hyperargininaemia. This pounds in patients with hyperargininaemia are ten to compound peak was named compound X as shown in hundred times higher than in controls, except for guanithe previous publications (1) (2) (3) . This peak, having more dinosuccinic acid. There is much controversy about the than one shoulder, appears complex and is Sakaguchi biosynthesis of guanidinosuccinic acid (5, 6) . and -naphthol positive. This peak is unstable and can degrade to 4-guanidinobutyric acid. By using the same The neurological disturbances in the patients with hypercolor factor as the nearest eluted guanidino compounds, argininaemia could be caused by hyperammonaemia, concentration values up to 5000 /g creatinine were but the high guanidino levels could also play a patholofound. Only traces are found in the urines of controls. gical role. Indeed, some guanidino compounds have conIn our preliminary study, this unknown compound peak vulsive effects on rabbits and cats when administered inwas identified as 2-oxo-5-guanidinovaleric acid (4) . tracisternally (7). 
Materials and Methods

Materials Apparatus
Liquid chromatography was performed on a Technicon AAI amino acid analyzer (Technicon Instruments, Tarrytown NY 10591). The column, length 140 cm, internal diameter 6.2 mm, was filled to 130 cm with Dowex 50 X 8 (resin Technicon Chromobeads® type A, particle size 21 ìðé). The operating flow rate was 0.5 mi/min.
The GC-MS apparatus was a Ribermag RIO-ÉÏ, fitted with a 2.5 m 3% SE 30 on chromosorb W column, (NERMAG, 92502, Rueil-Malmaison, Paris, France). Nuclear magnetic resonance spectra were determined with a Jeol JNM-PS 100 spectrometer operating at 100 MHz for protons (Jeol LTD 1418 Nakagami Akishima, Tokyo 196)
For desalting the unknown peak a jacketed Econo-column with nylon 3-way Luer Stopcocks, measuring 50 X 1.5 cm was used, (Bio-Rad, Richmond, California).
Reagents
For liquid chromatography, all the reagents were pro analysis. The resin used for desalting was Dowex 50W-X8 (H + ) (50 to 100 mesh) and obtained from Fluka (Fluka AG, CH-9470 Buchs, Switzerland). The silylating agents were obtained from Pierce (Pierce Chemical Company, Rockford 1L 61105). The dimethylpyrimidyl forming agent was acetylacetone, Merck (E. Merck, Darmstadt, West-Germany).
Specimens
The urines of the three patients, received through the care of one of us (Prof. Dr. //. G. Terheggen) were studied.
Methods
Enzymatic synthesis of 2-oxo-5-guanidinovaleric acid
2-Oxo-5-guanidinovaleric acid was synthesized according to the method described by Cooper et al. (8) with minor modifications. The enzymatic synthesis of 2-oxo-5-guanidinovaleric acid was controlled by nuclear magnetic resonance and GC-MS studies.
Nuclear magnetic resonance control of the enzymaticatty synthesized 2-oxo~5-guanidinovaleric acid
An aliquot was dissolved in D 2 O and the spectra were run at 100 MHz.
Desalting of the urine fraction corresponding with the unknown guanidino-positive compound peak
The eluent from the AAI analyzer, containing the unknown guanidino positive peak, was collected and desalted on the jacketed Econo-column of Dowex 50 W-X8 (H + ) (50*10 100 mesh). The jacket temperature was 3 °C. After applying the salt solution, the column was washed with distilled water. The elution was carried out with NH4OH (0.3 mol/1) long enough for the eluent to become basic. After this, the column was washed with a final volume of water. For a resin height of 25 cm, the first washing volume was 250 ml, the elution volume 250 ml and the final volume 75 ml. The used flow rate was 0.5 ml/min. Am ? monia was removed as soon as possible from the eluent with a rotavapor. Then the eluent was lyophilised and an aliquot was used for thin-layer chromatography and for GC-MS studies. Free mo no substituted guanidino compounds were analysed in parallel with amino adds as described byDurzan (9) . The elution procedure for liquid ion-ex can ge chromatography was according to Efron (10).
Liquid ion-exchange chromatography
Thin-layer chromatography
One dimensional thin-layer chromatography was performed in a chamber saturated with solvent by means of filter paper lining. Different solvents were used, e.g. n-propanol/acetic acid 1 mol/1 (150ml+ 50 ml). After chromatography, the plates were dried at room temperature. To locate the guanidino compounds, the plates were sprayed with Sakaguchi reagent prepared according to Jepson et al. (11) . Orange to red spots appeared.
Derivatization and GC-MS conditions
For GC-MS studies the guanidino compounds were converted to dimethylpyrimidyl derivatives by a method described by Mori et al. (12): aliquots of about 5 mg of enzymatically synthesized 2-oxo-5-guanidinovaleric acid and the desalted urine fraction were used. The dimethylpyrimidyl derivatives were silylated with 0.5 ml pyridine, 0.2 ml hexamethyldisilazane and 0.1 ml trimethylchlorosilane. The silylation occurred at room temperature. A helium flow of 20 ml/min was used. 
Results
The proton nuclear magnetic resonance studies have confirmed the findings of Cooper et al. (8) that 2-oxo-5-guanidinovaleric acid exists in equilibrium with its cyclic form. We have found 23% open and 77% closed form. Figure 2 gives the structure, and table 1 gives the chemical shift ä-values in ppm relative to internal DSS.
The shape and elution time of the unknown guanidinopositive compound peak were the same as those of enzymatically synthesized 2-oxo-5-guanidinpvaleric acid. One and the same compound peak was observed by chromatography of hyperargimnaenua urine together with the enzymatically synthesized 2-oxo.5-guanidinovaleric acid. The presence of more shoulders could be caused by modifications of the equilibrium during the elution. The elution time was the same as those of citrulline, glycine and alanine. The Rp value of enzymatically synthesized 2-oxo-5-guanidinovaleric acid was the same as those of the unknown guanidino positive urine peak. One and the same spot was observed by chromatography of a mixture of both fractions. Figure 3 acetic acid 1 mol/1 (150 ml + 50 ml). The first spot is a standard of 4-guanidinobutyric acid and arginine. The second spot is the unknown guanidino-positive compound peak, with 6-guanidinocaproic acid added as internal standard. The third spot is enzymatically synthesized 2-oxo-5-guanidinovaleric acid, with 6-guanidinocaproic acid added as internal standard. The fourth spot is a mixture of the urine fraction and enzymatically synthesized 2-oxo-5-guanidinovaleric acid. 2-Oxo-5-guanidinovaleric acid degrades to 4-guanidinobutyric acid ( fig. 3 ) in an aqueous medium enriched with oxygen. This is a chemical degradation (13) .
Since compounds containing a guanidino function are not suitable for GC-MS analysis, both enzymatically synthesized 2-oxo-5-guanidinovaleric acid and the unknown urine peak were converted into the silylated dimethylpyrimidyl derivative.
The mass spectrum of this derivative is depicted in figure  4 . The same fragment ions were observed for both the enzymatically synthesized product and the unknown urine peak.
No signal at m/z = 309 was observed because of the ease of water elimination from the cyclic form during the derivatisation procedure. The molecular ion (M) + at m/z = 291 was due to the dehydrated cyclic silylated dimethylpyrimidyl compound. Typical fragment ions are m/z = 276, 202, 174, 107 and 73 of which the origin is shown in figure 4 .
Ion m/z = 200 (base peak) can be explained by the elimination of (CH 3 ) 3 SiOH from the (M-H)+ -fragment ion (m/z = 290). Loss of a (CH 3 ) 3 SiOCO-radical from the (Ì-Ç)+-ßïç leads to m/z = 173.
Discussion
Only eight patients with hyperargininaemia, from five different families, have been described (14) (15) (16) (17) (18) . The first clinical symptoms such as irritability, coma and convulsions were the same as those of the other hyperammonaemias. The development of the patients is characterised by neurological degradation, resulting in spasticity, athetosis and ataxia. They are also mentally retarded. Hepatomegaly and an increase of the activity of transaminases and aldolases was also seen in our patients. Different problems arise in these patients: a) In view of the neurological picture of the patients, the main question is: is there a correlation between the neurological symptoms and the elevated arginine and guanidino compounds in the biological fluids?
b) In the biochemistry of these patients, there are several interesting points like the normal or low normal values of blood urea, in contrast with arginase deficiency. Three possibilities for this anomaly have been suggested: 1. The patients with hyperargininaemia try to metabolize their high arginine load. Therefore elevated levels of guanidino compounds were to be expected. As can be seen in table 2, the excretion values of the monosubstituted guanidino compounds are ten to hundred times higher than those of controls, except for guanidinosuccinic acid. The excretion value of guanidinosuccinic acid is even lower than in controls. Guanidinosuccinic acid does not seem to be synthesized from arginine.
2. Little is known about the synthesis of guanidino compounds in vivo. Guanidinoacetic acid is formed by a transamidination reaction: the amidino group of arginine is transferred to glycine (22) . Guanidinoacetic acid is an intermediate in the biosynthesis of creatine and creatinine. 4-Guanidinobutyric acid can also be formed by transamidination from arginine to 4-aminobutyric acid (23) . N-a-acetylarginine could be formed by an acetylation of arginine. And deammation of arginine, followed by an hydrogenation could give argininic acid.
Patients with hyperargininaemia are characterised by an abnormal metabolism of the guanidino compounds. In Tab. 2. Excretion values of some monosubstituted guanidino compounds in urine.
